Clinical Trial Update: A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating the combination of Anvumetostat with IDE397 in MTAP-null solid tumors has completed, including MTAP-null non-small cell lung cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Solid Tumors

Drugs mentioned

• Anvumetostat (Anvumetostat)
• IDE397

Snippet

Sponsor: Amgen | Conditions: MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors | Phase 1, Phase 2 | Status: COMPLETED